liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A new fast-melting oral formulation of desmopressin: A pharmacodynamic study in children with primary nocturnal enuresis
Dept Pediatric Nephrology, University of Gent, .
Linköping University, Faculty of Health Sciences. Linköping University, Department of Molecular and Clinical Medicine, Pediatrics. Östergötlands Läns Landsting, Centre of Paediatrics and Gynecology and Obstetrics, Department of Paediatrics in Linköping.
Dept of Pediatric Nephrology, Brussels, Belgium.
Dept of Pediatrics Urology, University of Gent .
Show others and affiliations
2006 (English)In: BJU International, ISSN 1464-4096, Vol. 97, no 3, 603-609 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To determine the pharmacodynamic properties of a new oral lyophilisate formulation of desmopressin (in single doses of 30, 60, 120, 240, 360 or 480 μg) in children with known primary nocturnal enuresis (PNE) and thus identify those dosages that could provide a duration of action corresponding to a typical length of night-time sleep in children with PNE, additional objectives were to determine the safety and tolerability of desmopressin in this population. PATIENTS AND METHODS: Children with PNE (mean three or more wet nights/week), aged 6-12 years, were randomized into a double-blind, placebo-controlled study. An overhydration technique was used before dosing to suppress endogenous vasopressin production and thereby ensure that any antidiuresis could be attributed to treatment. Dosing with desmopressin or placebo occurred when urinary production was >0.13 mL/min/kg. Urinary volume, osmolality and duration of urinary-concentrating action (above three threshold levels: 125, 200 and 400 mOsm/kg) were determined as endpoints. RESULTS: All 72 participants receiving desmopressin had a pharmacodynamic response to the drug, while there was no change in urinary output in the 12 placebo-treated patients. There was a clear relationship between desmopressin dose and duration of action and osmolality during action, although the three highest-dose groups had similar results. The mean duration of action of desmopressin at the lowest osmolality threshold level was 3.6-10.6 h, according to dose, for the highest threshold, the values were 1.3-8.6 h. CONCLUSION: Desmopressin, as the oral lyophilisate, causes a marked decrease in urinary output in hydrated children with PNE. A small dose range (120-240 μg) is likely to control diuresis for a period corresponding to a night's sleep (7-11 h) in most children with PNE. However, some patients might require a higher dose to obtain antidiuresis for the complete night. © 2006 BJU International.

Place, publisher, year, edition, pages
2006. Vol. 97, no 3, 603-609 p.
Keyword [en]
desmopressin, primary nocturnal enuresis, pharmacodynamics, osmolality, chiidren
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-35912DOI: 10.1111/j.1464-410X.2006.05999.xLocal ID: 29057OAI: diva2:256760
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2011-01-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Mattsson, Sven
By organisation
Faculty of Health SciencesPediatricsDepartment of Paediatrics in Linköping
In the same journal
BJU International
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 19 hits
ReferencesLink to record
Permanent link

Direct link